Covaxin


Bharat Biotech's Covaxin&nbsp

Key Highlights

  • AIIMS is one of the centres for trial of the COVID-19 vaccine on children

  • The second dose trial of Covaxin for children aged 2-6 years will take place next week

  • COVID-19 vaccine for children could be available in September, said Dr Randeep Guleria

New Delhi: All India Institute of Medical Sciences (AIIMS), New Delhi is set to start the second dose trial of Bharat Biotech’s COVID-19 vaccine, Covaxin for children aged 2-6 years from next week. AIIMS is one of the centres for the trial of the COVID-19 vaccine for those below 18 years.

The second dose of the vaccine has already been given to children aged between 6 to 12 years at AIIMS, Delhi.

Earlier, AIIMS director Dr Randeep Guleria had said the vaccine for children could be available in September.

Interim report likely to be released by August

To conduct the trials, the children have been segregated into categories as per their age and 175 children of each age group have been included.

Once they get the second dose, an interim report is likely to be released by August which will present a clear picture about the safety of vaccines on children.

Earlier this week, the Union government informed the Delhi High Court that clinical trials of COVID-19 vaccines for children under 18 years of age would be completed soon.

Besides Covaxin, trials for Zydus Cadila’s vaccine for children are also currently underway.

Statutory nod for Zydus Cadila vaccine for 12-18 age-group soon: Centre to HC

The Centre also informed the Court that Zydus Cadila’s DNA vaccine has concluded its clinical trial for the age group of 12 to 18.

“It is submitted that Zydus Cadila, which is developing DNA vaccines has concluded its clinical trial for between the age group of 12 to 18 and subject to the statutory permissions, the same may be available in near future for children of the age group of 12 to 18 years of age,” it said.

The Union government also said that vaccination is its topmost priority and all efforts are being made to achieve an objective of 100 per cent vaccination in the shortest time possible.



Source link